
The New Era of Feline Diabetes Management
The recent approval of two SGLT2 inhibitors for treating type 2 diabetes in cats marks a significant advancement in veterinary medicine. Bexacat (bexagliflozin) and Senvelgo (velagliflozin) are now on the market as sole agents specifically for feline diabetes. According to Dr. Ellen Behrend, these medications offer a new frontier for managing a disease that affects many cats, with the majority likely suffering from type 2 diabetes.
Understanding the Differences
Currently, both drugs are considered rather similar until further comparative studies reveal distinct differences. Bexacat comes in pill form, whereas Senvelgo is a liquid, making the choice largely dependent on the owner's preference. This flexibility is particularly important for pet owners who might struggle with administering medication, as the method can significantly impact compliance.
Identifying Suitable Candidates for Treatment
Behrend emphasizes that proper selection of candidates is vital. A cat may qualify for SGLT2 inhibitors if it is otherwise healthy, showing no signs of severe illness such as vomiting or diarrhea. Notably, the FDA advises that these medications should not be used in cats previously treated with insulin. However, clinicians might consider off-label use in some situations, allowing more flexibility in treatment options.
What Practitioners Should Watch For
Monitoring is crucial. Practitioners must ensure the absence of ketones in urine or significant elevation in beta-hydroxybutyrate levels in the blood before initiating these medications. This requirement confirms that these cats are well-suited for SGLT2 therapy, which can otherwise lead to complications.
New Opportunities for Veterinary Clinics
As these SGLT2 inhibitors become more widely known and utilized, there’s an excellent opportunity for veterinary practices to educate clients on the benefits and particulars of these medications. By optimizing diabetes management protocols with these newly approved treatments, veterinarians can potentially improve health outcomes for diabetic cats and enhance their practice’s reputation in compassionate and effective care.
In summary, understanding the implications of SGLT2 inhibitors like Bexacat and Senvelgo not only equips veterinary professionals with advanced treatment options but also paves the way for better outcomes for feline patients. Stay updated with the latest veterinary innovations to ensure your clinic remains at the forefront of feline healthcare.
Write A Comment